Gliclazide modified release

Drugs

Volumn 65, Issue 10, 2005, Pages 1449-1450

  Rambiritch, Virendra ^a   Naidoo, Poobalan ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; GLUCOSE; METFORMIN;

ADD ON THERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS;

DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT COMPLIANCE; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 22944470088     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565100-00009     Document Type: Letter

References (24)

1. McGavin JK, Perry CM, Goa KL. Gliclazide modified release: new formulation profile. Drugs 2002; 62 (9): 1357-64
2. Harrower A. Gliclazide modified release. Drugs 2002; 62 (9): 1365-6
3. Guillausseau P-J. Gliclazide modified release. Drugs 2002; 62 (9): 1365-6
4. Francillard M, Frey N, Paraire M, et al. Pharmacokinetics of Diamicron modified release (MR) in 1007 type 2 diabetic patients [abstract]. European Union Geriatric Medicine Society Annual Meeting; 2001 Aug 29-Sep 1; Paris
5. Frey N, Laveille C, Paraire M, et al. Effect of gliclazide in a new once a day formulation. In: Danhof M, Karlsson M, Powell RJ, editors. Measurement and kinetics of in vivo drug effects: advances in simultaneous pharmacokinetic/ pharmacodynamic modeling; 2002 Apr 24-27; Noordwijkerhout. Amsterdam: Leidin University, 2002: 154-60
6. Frey N, Laveille C, Paraire M, et al. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br J Clin Pharmacol 2003; 55: 147-57
7. Drouin P, Standl E, for the Diamicron MR Study Group. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabetes Obes Metab 2004; 6: 414-21
8. Diamicron® MR Study Group, Drouin P. Diamicron. MR once daily is effective and well tolerated in type 2 diabetes: a double blind, randomized, multinational study. J Diabetes Complications 2000; 14: 185-91
9. Li GW, Pan CY, Gao Y, et al. The efficacy and safety of slow-released-gliclazide in type 2 diabetes mellitus [abstract]. Zhonghua Nei Ke Za Zhi 2004; 43 (7): 510-4
10. Guillausseau PJ, Greb W. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily. Diabetes Metab 2001; 27: 133-7
11. Ionescu-Tirgoviste C, Gavrila L, et al. NIDDM: new once-daily intervention for type 2 diabetes mellitus. Diaprel MR. Rom J Intern Med 2004; 42 (2): 431-40
12. Matsuda A, Kuzuya T, Sugita Y, et al. Plasma levels of glibenclamide in diabetic patients during routine clinical administration determined by specific radioimmunoassay. Horm Metab Res 1983; 15: 425-8
13. Sartor G, Melander A, Schersten B, et al. Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects glibenclamide. Diabetologia 1980; 18 (1): 17-22
14. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65 (3): 385-411
15. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303
16. Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview. Diabetes 2004; 53 Suppl. 3: 151-5
17. Wahlin-Boll E, Sartor G, Melander A. Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol 1981; 22: 21-5
18. Stenman S, Melander A, Groop P-H, et al. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993; 118: 169-72
19. Simonson DC, Kourides IA, Feinglos M, et al., for the Glipizide Gastrointestinal Therapeutic System Study Group. Efficacy, safety, and dose response characteristics of glipizide gastrointestinal therapeutic system on glycaemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 1997; 20: 597-606
20. Robertson L, Jackson L. Sulphonylureas (specifically glibenclamide) and their correct dosage [letter]. S Afr Med J 1989; 76 (6): 286-9
21. Rambiritch V. The pharmacokinetics and pharmacodynamics of glibenclamide in type 2 diabetics [dissertation]. KwaZulu-Natal: University of KwaZulu-Natal, 2004
22. Jonsson A, Hallengren B, Rydberg T, et al. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab 2001; 3: 403-9
23. Shaw KM, Wheeley MSG, Cambell DB, et al. Home blood glucose monitoring in non-insulin dependent diabetes: the effect of gliclazide on blood glucose and weight control, a multiple trial. Diabet Med 1985; 2: 484-90
24. Palmer KJ, Brogden RN. Gliclazide-an update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 1993; 46 (1): 92-125